- Home
- GMAB vs BIIB Comparison
GMAB vs BIIB Comparison
Compare GMAB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BIIB
- Stock Information
- Founded
- GMAB 1999
- BIIB 1978
- Country
- GMAB Denmark
- BIIB United States
- Employees
- GMAB N/A
- BIIB N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GMAB Health Care
- BIIB Health Care
- Exchange
- GMAB Nasdaq
- BIIB Nasdaq
- Market Cap
- GMAB 17.4B
- BIIB 18.7B
- IPO Year
- GMAB N/A
- BIIB 1991
- Fundamental
- Price
- GMAB $28.66
- BIIB $155.51
- Analyst Decision
- GMAB Strong Buy
- BIIB Buy
- Analyst Count
- GMAB 7
- BIIB 24
- Target Price
- GMAB $41.50
- BIIB $174.62
- AVG Volume (30 Days)
- GMAB 2.6M
- BIIB 1.6M
- Earning Date
- GMAB 11-06-2025
- BIIB 10-30-2025
- Dividend Yield
- GMAB N/A
- BIIB N/A
- EPS Growth
- GMAB 132.41
- BIIB N/A
- EPS
- GMAB 25.10
- BIIB 10.97
- Revenue
- GMAB $3,845,670,022.00
- BIIB $10,065,900,000.00
- Revenue This Year
- GMAB $24.92
- BIIB $2.97
- Revenue Next Year
- GMAB $15.97
- BIIB N/A
- P/E Ratio
- GMAB $11.14
- BIIB $14.17
- Revenue Growth
- GMAB 29.57
- BIIB 4.77
- 52 Week Low
- GMAB $17.24
- BIIB $110.04
- 52 Week High
- GMAB $33.65
- BIIB $176.95
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- BIIB 59.29
- Support Level
- GMAB $28.08
- BIIB $148.90
- Resistance Level
- GMAB $29.35
- BIIB $157.79
- Average True Range (ATR)
- GMAB 0.65
- BIIB 4.78
- MACD
- GMAB -0.27
- BIIB 0.43
- Stochastic Oscillator
- GMAB 25.93
- BIIB 82.77
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.